MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well positron emission tomography (PET) scan using
18F-fluoromisonidazole works when given together with magnetic resonance imaging (MRI) ) in
assessing tumor hypoxia in patients with newly diagnosed glioblastoma multiforme (GBM).
Diagnostic procedures, such as MRI and PET scan using 18F-fluoromisonidazole (FMISO), may
help predict the response of the tumor to the treatment and allow doctors to plan better
treatment.